Shareholders’ Deficit

6 Months Ended

Jun. 30, 2022

Shareholders’ Deficit [Abstract]

SHAREHOLDERS’ DEFICIT

NOTE 5 – SHAREHOLDERS’ DEFICIT

Common Stock - Option Grants

The Company recorded no compensation expense for the six months ended June 30, 2022 and 2021. As of June 30, 2022, there was $0 in unrecognized compensation expense.

The Company did not grant any options during the six months ended June 30, 2022, none expired, and none were cancelled. There are no unvested options as of June 30, 2022. 

For warrants granted to non-employees in exchange for services, the Company recorded the fair value of the equity instrument using the Black-Scholes pricing model unless the value of the services is more reliably measurable.

The Company did not grant any warrants during the six months ended June 30, 2022, and no warrants were exercised, 5000 expired, and none were cancelled. At June 30, 2022, there were 5,000 warrants outstanding, with a weighted exercise price of $56.00 and a weighted remaining contractual life of 0.6 years.

The aggregate intrinsic value of the 5,000 outstanding and exercisable warrants at June 30, 2022, and December 31, 2021 was $0. The intrinsic value is the difference between the closing stock price on June 30, 2022, and 2021, and the exercise price, multiplied by the number of in-the-money warrants had all warrant holders exercised their warrants on June 30, 2022, or December 31, 2021.